Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience;Láser-ranibizumab para tratar retinopatía del prematuro en estadio umbral-preumbral. Tres años de experiencia

Cirugia y Cirujanos

Volumn 79, Issue 3, 2011, Pages 225-232

  Orozco Gómez, Luis Porfirio ^a   Hernández Salazar, Leonor ^a   Moguel Ancheita, Silvia ^a   Ramírez Moreno, María Adela ^a   Morales Cruz, María Verónica ^a  

^a CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

Author keywords

Laser; Prematurity; Ranibizumab; Retinopathy

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; RANIBIZUMAB;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INTELLECTUAL IMPAIRMENT; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; LOW BIRTH WEIGHT; MALE; MULTIMODALITY CANCER THERAPY; NEWBORN; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREMATURITY; PROSPECTIVE STUDY; PSYCHOMOTOR DISORDER; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; TREATMENT OUTCOME; VASODILATATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INTELLECTUAL DISABILITY; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PSYCHOMOTOR DISORDERS; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; TREATMENT OUTCOME; VASODILATION;

EID: 79959970149     PISSN: 00097411     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Roum JH, Bohild R, Mc Elvancy NG. Screening of premature infants for retinopathy of prematurity. Pediatrics 1997;86:1277-1282.
2. Yannuzzi LA, Guyet DR, Green WR. The Retina Atlas. St. Louis: Mosby; 1996 pp. 470-479
3. Todd DJ. Retinopathy of prematurity in infants less than 32 weeks gestation at birth in New South Wales in 1993-1994. Ped Child Health 1999;35:355-357.
4. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: preliminary report. Am J Ophthalmol 1942;25:203-204.
5. Shih SC, Ju M, Liu N, Smith LE. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003;112:50-57. (Pubitemid 38056375)
6. Capone A, Díaz-Rohena R. Diode laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 1993;16:444-450 (Pubitemid 23299489)
7. Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology 1993;100:238-244. (Pubitemid 23056538)
8. Landers MB III, Toth CA. Treatment of retinopathy of prematurity with argon laser photocoagulation. Arch Ophthalmol 1992;110:44-47.
9. Bakri SV, Snyder MR, Reide JM, Pulido JS, Ezza MK, Singh RJ. Pharmakokinetics of intravitreal ranibizumab (lucentis). Ophthalmology 2007;114:2179-2182.
10. Allegaert K, Van de Velde M, Casteels I, Naulaers G, Vanhole C, Devlieger H. Cryotherapy for threshold retinopathy: perioperative management in a single center. Am J Perinatol 2003;20:219-226. (Pubitemid 37070590)
11. Ben-Sira I, Nissenkom I. Long term results of cryotherapy for active stages of retinopathy of prematurity. Ophthalmology 1986;3:1423-1428 (Pubitemid 17211862)
12. Coats DK, Miller AM, McCreery KM, Holz ER, Paysse EA. Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology 2004;111:1894-1898. (Pubitemid 39311843)
13. Orozco-Gómez L, Ruiz-Morfín I. Prevalencia de la retinopatía del prematuro. 12 años de detección en el Centro Médico Nacional 20 de Noviembre. Cir Cir 2006;74:3-9.
14. González-Urquidi J, De la Fuente-Torres MA. Incidencia de la retinopatía del prematuro en el Hospital Dr. Manuel Gea González. Rev Mex Oftalmol 2004;78:1-4.
15. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:1379-1381.
16. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Ophthalmology 2009;148:536-543.
17. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RS. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859 (Pubitemid 46635858)
18. Meadow W, Santos J. Reflexiones éticas sobre los cuidados intensivos neonatales. Pediatrics 2009;67:77-79.